Risk factors for and clinical implications of mixed Candida/bacterial bloodstream infections
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Kim, S. -H. | - |
dc.contributor.author | Yoon, Y. K. | - |
dc.contributor.author | Kim, M. J. | - |
dc.contributor.author | Sohn, J. W. | - |
dc.date.accessioned | 2021-09-06T05:36:32Z | - |
dc.date.available | 2021-09-06T05:36:32Z | - |
dc.date.created | 2021-06-14 | - |
dc.date.issued | 2013-01 | - |
dc.identifier.issn | 1198-743X | - |
dc.identifier.uri | https://scholar.korea.ac.kr/handle/2021.sw.korea/104281 | - |
dc.description.abstract | Mixed Candida/bacterial bloodstream infections (BSIs) have been reported to occur in more than 23% of all episodes of candidaemia. However, the clinical implications of mixed Candida/bacterial BSIs are not well known. We performed a retrospective case-control study of all consecutive patients with candidaemia over a 5-year period to determine the risk factors for and clinical outcomes of mixed Candida/bacterial BSIs (cases) compared with monomicrobial candidaemia (controls). Thirty-seven (29%) out of 126 patients with candidaemia met the criteria for cases. Coagulase-negative staphylococci were the predominant bacteria (23%) in cases. In multivariate analysis, duration of previous hospital stay >= 7 weeks (odds ratio (OR), 2.86; 95% confidence interval (CI), 1.09-7.53), prior antibiotic therapy >= 7 days (OR, 0.33; 95% CI, 0.14-0.82) and septic shock at the time of candidaemia (OR, 2.60; 95% CI, 1.14-5.93) were significantly associated with cases. Documented clearance of candidaemia within 3 days after initiation of antifungal therapy was less frequent in cases (63% vs. 84%; p = 0.035). The difference in the rate of treatment failure at 2 weeks was not significant between cases (68%) and controls (62%; p = 0.55). The crude mortality at 6 weeks and survival through 100 days did not differ between the two patient groups (p = 0.56 and p = 0.80, respectively). Mixed Candida/bacterial BSIs showed a lower clearance rate of candidaemia during the early period of antifungal therapy, although the treatment response and survival rate were similar regardless of concurrent bacteraemia. Further studies on the clinical relevance of species-specific Candida-bacterial interactions are needed. | - |
dc.language | English | - |
dc.language.iso | en | - |
dc.publisher | ELSEVIER SCI LTD | - |
dc.subject | CANDIDA-ALBICANS | - |
dc.subject | STAPHYLOCOCCUS-AUREUS | - |
dc.subject | ORGAN FAILURE | - |
dc.subject | IN-VITRO | - |
dc.subject | SEPSIS | - |
dc.subject | MORTALITY | - |
dc.subject | EPIDEMIOLOGY | - |
dc.subject | INHIBITION | - |
dc.subject | BACTEREMIA | - |
dc.subject | GUIDELINES | - |
dc.title | Risk factors for and clinical implications of mixed Candida/bacterial bloodstream infections | - |
dc.type | Article | - |
dc.contributor.affiliatedAuthor | Kim, S. -H. | - |
dc.contributor.affiliatedAuthor | Yoon, Y. K. | - |
dc.contributor.affiliatedAuthor | Kim, M. J. | - |
dc.contributor.affiliatedAuthor | Sohn, J. W. | - |
dc.identifier.doi | 10.1111/j.1469-0691.2012.03906.x | - |
dc.identifier.scopusid | 2-s2.0-84871621449 | - |
dc.identifier.wosid | 000314650200016 | - |
dc.identifier.bibliographicCitation | CLINICAL MICROBIOLOGY AND INFECTION, v.19, no.1, pp.62 - 68 | - |
dc.relation.isPartOf | CLINICAL MICROBIOLOGY AND INFECTION | - |
dc.citation.title | CLINICAL MICROBIOLOGY AND INFECTION | - |
dc.citation.volume | 19 | - |
dc.citation.number | 1 | - |
dc.citation.startPage | 62 | - |
dc.citation.endPage | 68 | - |
dc.type.rims | ART | - |
dc.type.docType | Article | - |
dc.description.journalClass | 1 | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
dc.relation.journalResearchArea | Infectious Diseases | - |
dc.relation.journalResearchArea | Microbiology | - |
dc.relation.journalWebOfScienceCategory | Infectious Diseases | - |
dc.relation.journalWebOfScienceCategory | Microbiology | - |
dc.subject.keywordPlus | CANDIDA-ALBICANS | - |
dc.subject.keywordPlus | STAPHYLOCOCCUS-AUREUS | - |
dc.subject.keywordPlus | ORGAN FAILURE | - |
dc.subject.keywordPlus | IN-VITRO | - |
dc.subject.keywordPlus | SEPSIS | - |
dc.subject.keywordPlus | MORTALITY | - |
dc.subject.keywordPlus | EPIDEMIOLOGY | - |
dc.subject.keywordPlus | INHIBITION | - |
dc.subject.keywordPlus | BACTEREMIA | - |
dc.subject.keywordPlus | GUIDELINES | - |
dc.subject.keywordAuthor | Bacteraemia | - |
dc.subject.keywordAuthor | candidaemia | - |
dc.subject.keywordAuthor | co-infection | - |
dc.subject.keywordAuthor | risk factors | - |
dc.subject.keywordAuthor | treatment outcome | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
(02841) 서울특별시 성북구 안암로 14502-3290-1114
COPYRIGHT © 2021 Korea University. All Rights Reserved.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.